| Objective:Epithelial ovarian tumors are the most common gynecologicalclinical disease, including epithelial ovarian cancer, benign ovarian epithelial tumors,ovarian endometrial endometriosis, pelvic inflammatory mass and so on.In recentyears, the malignant epithelial ovarian cancer has become a serious threat towomen’s lives.This article detect the content of serum carbohydrate antigen125(CA125) and angiopoietin-like protein3(ANGPTL3) of epithelial ovarian cancer,benign ovarian epithelial tumors, ovarian endometrial endometriosis, pelvicinflammatory mass patients and normal ovarian subjects to explore the significanceof serum CA125and ANGPTL3to epithelial ovarian tumor diagnosis.Methods:Enzyme linked immunosorbent assay(ELISA) was used to detect thelevel of preoperative fasting8hours’ ANGPTL3in55patients who ware diagnosedof benign ovarian tumors (20cases of benign ovarian epithelial tumors,20cases ofovarian endometrial endometriosis,15cases of pelvic inflammatory mass),40casesof epithelial ovarian cancer and20cases of normal ovarian subjects in obstetrics andgynecology of China-Japan Union Hospital of Jilin University during January of2011to December of2012.ECLIA was used to routine test CA125levels by thedepartment of nuclear medicine laboratory of China-Japan Union Hospital of JilinUniversity.Results:1.Epithelial ovarian cancer group serum CA125level was893.5±1203.7U/ml, benign ovarian disease group serum CA125level was46.7±32.7U/ml,control group serum CA125level was25.9±13.8U/ml. Epithelialovarian cancer group serum CA125levels significantly higher than benign ovariandisease group and the control group (P<0.05), benign ovarian disease group serumCA125levels were significantly higher than the control group (P<0.05). Epithelial ovarian cancer serum group serum ANGPTL3level was129.9±99.1ng/ml,theovarian benign disease group serum ANGPTL3level was401.4±108.5ng/ml,control group serum AGPTL3level was389.1±124.4ng/ml. The epithelial ovariancancer group serum ANGPTL3level significantly higher than benign ovariandisease group and the control group (P <0.05),There was no significant difference ofANGPTL3level between benign ovarian disease group and the control group(P>0.05).2.Epithelial ovarian cancer group serum CA125positive rate was65%, benignovarian disease group serum CA125positive rate was32.7%, the control groupserum CA125positive rate was5%. Epithelial ovarian cancer group serum CA125positive rate was significantly higher than benign ovarian disease group and the thecontrol group (P<0.05), benign ovarian disease group serum CA125positive ratewas significantly higher the control group (P<0.05). Epithelial ovarian cancer groupserum ANGPTL3positive rate was80.25%, ovarian benign diseases group serumANGPTL3positive rate was5.4%, the control group the serum ANGPTL3positiverate was5%. Epithelial ovarian cancer group serum ANGPTL3positive rate wassignificantly higher than benign ovarian disease group and the control group(P<0.05),There was no significant difference of ANGPTL3positive rate betweenbenign ovarian disease group and the control group(P>0.05).3.Benign ovarian epithelial tumor group serum CA125levels was23.0±10.2U/ml, the positive rate was5%;ovarian endometriosis group serum CA125levelwas69.7±73.9U/ml positive rate was50%; pelvic inflammatory mass group serumCA125levels was78.4±108.3U/ml, the positive rate was46.7%; the control groupserum CA125level was25.9±13.8U/ml positive rate was5%.Ovarianendometriosis group and pelvic inflammatory mass group serum CA125levels andthe positive rate were significantly higher than Benign ovarian epithelial tumorgroup and the control group(P<0.05).There was no significant difference of CA125levels and the positive rate between Ovarian endometriosis group and pelvicinflammatory mass group(P>0.05),There was no significant difference of CA125 levels and the positive rate between benign ovarian epithelial tumor group and thecontrol group(P>0.05).4.Benign ovarian epithelial tumor group serum ANGPTL3level was539.7±139.6ng/ml, the positive rate was0;ovarian endometriosis group serum ANGPTL3level was423.5±268.7ng/ml, the positive rate was10%; pelvic inflammatory massserum ANGPTL3level was413.6±197.9ng/ml, the positive rate was6.7%to389.1±124.4ng/ml; the control group serum ANGPTL3lever was389.1±124.4ng/ml,thepositive rate was5%.There were no significant difference of serum ANGPTL3leveland the positive rate among Benign ovarian epithelial tumor group, ovarianendometriosis group, pelvic inflammatory mass group and the control group(P>0.05).5.The diagnosis sensitivity and specificity of Serum CA125to epithelialovarian cancer were65%(26/40) and67.3%(37/55), The diagnosis sensitivity andspecificity of serum ANGPTL3to epithelial ovarian cancer were80.25%(33/40)and94.5%(52/55), The diagnosis sensitivity and specificity of serum CA125+ANGPTL3to epithelial ovarian cancer were85%(34/40) and63.6%(35/55).Independently detection,the sensitivity of serum CA125was significantlylower than serum ANGPTL3(P<0.05), the specificity of serum CA125wassignificantly lower than serum ANGPTL3(P<0.05);the sensitivity of both jointdetection was significantly higher than independently serum CA125detection(P<0.05),the sensitivity of both joint detection was higher thanindependently serum AGPTL3detection(P<0.05),but there was no significantdifference(P>0.05);the specificity of both joint detection was lower thanindependently serum CA125detection,but there was no significant difference(P>0.05),the specificity of both joint detection was significantly lower thanindependently serum AGPTL3(P<0.05).Conclusion:1.CA125and ANGPTL3has an important role in distinguishbenign and malignant of epithelial ovarian neoplasms, both of them can be used as atumor marker for preoperative differential diagnosis.2.CA125has certain clinical diagnosis significance on ovarian endometriosis group, pelvic inflammatory massgroup.3.ANGPTL3can be as a new tumor marker for ovarian cancer.4.Independently serum ANGPTL3detection for diagnosis of epithelial ovarian canceris the best,serum CA125joint ANGPTL3detection was better than independentlyserum CA125detection for the diagnosis of epithelial ovarian cance. |
PDF Full Text Request